Therapeutic Horizons in Metabolic Dysfunction-Associated Steatohepatitis

The authors focus on pharmacological treatments in advanced development for metabolic dysfunction–associated steatohepatitis, including incretin-based therapies, metabolic modulators, and novel agents such as fatty acid synthase inhibitors.